Trial · NCT02294955
Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation (CAPTAF Trial)
NCT02294955, Not applicable, Unknown, Uppsala University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation (CAPTAF Trial). Trials, record NCT02294955. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02294955
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation (CAPTAF Trial)
- NCT number
- NCT02294955
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 152 participants, actual
- Lead sponsor
- Uppsala University Hospital
- Conditions
- Atrial Fibrillation, Quality of Life
- Interventions
- Catheterablation, Amiodarone, Sotalol, Flecainide, Propafenone, Disopyramide, Dronedarone
- First posted
- 2014-11-19
- Last updated
- 2017-05-09
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | quality of life | 12 months | General Health related Quality of Life; Short Form (SF) 36 |
| Secondary | atrial fibrillation burden | 12, 24, 36 and 48 months | Total time spent in and number of episodes of atrial fibrillation, Frequency of symptomatic respectively asymptomatic episodes of AF assessed by implantable event recorder. |
| Secondary | Composite of morbidity | 12, 24, 36 and 48 months | Stroke, systemic embolic events, transient ischemic attack (TIA), major bleeding, cardiovascular hospitalizations, pacemaker implantation, all cause Death. |
| Secondary | Hospitalization | 12, 24, 36 and 48 months | Total number of hospitalization days and time to first event of hospitalization days due to cardiovascular reasons and atrial fibrillation |
| Secondary | Quality of Life | 12, 24, 36 and 48 months | Quality of Life by SF-36, all domains and time-points; symptom severity score (SSQ); European Heart Rhythm Association (EHRA) Symptom Classification. |
| Secondary | Health care use and economy | 24 and 48 months | EuroQoL (EQ) 5D, a standardised instrument for measure of health outcome, COSTs for hospitalization and outpatient visits related to and not related to AF, treatment costs, and including corrections for background variables regarding social economic status. |
| Secondary | Success of treatment | 12 and 48 months | Baseline predictors for symptom-based response (symptom success) and rhythm-based response. |
| Secondary | Physical capacity | 12, 24, 36 and 48 months | Exercise/Physical capacity and % of predicted max. as well as duration |
| Secondary | Atrial area and function | 12, 24, 36 and 48 months | Left atrial area and function, Right atrial area and function (from Echocardiography and corrected for body surface area. |
| Secondary | Adverse events | 12, 24, 36 and 48 months | Incidence, intensity and relationship of Adverse Events |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02294955
GET https://conductscience.org/api/trials/v1/NCT02294955/registered